Search for: "Novartis Ag"
Results 301 - 320
of 440
Sorted by Relevance
|
Sort by Date
22 Sep 2006, 12:17 pm
While the FDA has approved Novartis AG's Omnitrope hormone, there has not been a change in the stance taken by the FDA on generic biotechnology drugs. [read post]
21 Jul 2013, 5:38 pm
Lipimile, Director & Chief Executive Officer, COMESA Competition Commission • Ali Haddou Ruiz, Executive Secretary, The Federal Competition Commission, Mexico • Michele Piergiovanni, Case Manager, European Commission Merger Control Unit, European Commission • Carel Maske, Senior Attorney, Antitrust, Microsoft EMEA • Martin Commons, Senior Competition/Antitrust Counsel, BHP Billiton • Joerg Haering, Division General Counsel Legal & Compliance, Siemens • Susan… [read post]
16 Mar 2011, 3:50 am
Actavis (Kluwer Patent Blog) Valsartan – Norway: Valsartan case goes on appeal: Novartis v Actavis (The SPC Blog) Xeloda (Capecitabine) – US: Hoffmann-La Roche files patent infringement complaint against Accord following Para IV challenge (Patent Docs) [read post]
6 Apr 2011, 12:18 am
Chiron Healthcare & Novartis (EPLAW) India firm on ‘NO’ to data exclusivity (SiNApSE) (Generic Pharmaceuticals and IP) (Spicy IP) (Spicy IP) US: CAFC hears oral arguments on patentability of DNA claims: American Molecular Pathology, et. al, v. [read post]
5 Nov 2017, 3:10 pm
In Novartis AG v Generics (UK) Ltd (trading as Mylan) [2012] [read post]
24 Aug 2020, 12:00 am
Finding it difficult to keep up with an ever-changing world in the midst of a health, environmental, social and political crisis, while keeping up with patent law? [read post]
23 Feb 2015, 2:55 am
| Dutch diverge with English as Novartis prevails on Zoledronic Acid in Netherlands | Slogan and TMs | The coffee capsule wars | Declining public trust in innovation | IPEC’s ruling in Global Flood Defence Systems & Another v Van den Noort Innovations BV & Others | Again on CJEU ruling in Case C-419/13 Art & Allposters | Biotech financing: the risk components, ‘going long’ and patents as knowledge currency. [read post]
10 Mar 2010, 5:22 am
(Patent Docs) (GenericsWeb) Protonix (Pantoprazole) - US: District Court dismisses Wyeth Lanham Act case concerning generic Protonix, but leaves the door open for further litigation (FDA Law Blog) ReFacto (Moroctocog alfa)- US: Novartis prevails over Pfizer in ReFacto suit (Patent Docs) Vytorin (Ezetimibe, Simvastatin) – US: Infringement of patent following a Paragraph IV certification: Schering Corp. et al. v. [read post]
12 Apr 2011, 10:07 pm
Infringement proceedings by the European Commission against Italy (Kluwer Patent Blog) India approves free access to important portions of the Traditional Knowledge Digital Library (TK Community) (Spicy IP) USPTO proposes changes to PTA and PTE provisions (Patent Docs) US: FDA issues warning letter for failure to submit animal study reports in an IDE (FDA Law Blog) US: AMP v USPTO – oral argument at the Federal Circuit (Patent Docs) US: A historical perspective on the gene patent controversy… [read post]
6 Sep 2010, 10:01 am
Another failed mistake of age defense based on a MySpace misreported age, this time in the context of a military discharge [read post]
29 Jun 2011, 3:34 am
(Patent Docs) Deferacirox – India: Cipla wins pre grant opposition (593/CHENP/2005): Novartis v. [read post]
11 Jan 2011, 11:07 pm
General Steve Burrill makes predictions for the biotech industry in 25th annual report (Patent Docs) Australia: ‘Innovation’ patents in Australia – AMI innovation patent and US investment (IPBiz) Australia: Extension of patent term for pharmaceuticals in Australia: AAT decision in LTS Lohmann Therapie Systeme AG and Schwarz Pharma Ltd and Commissioner of Patents (Patent Baristas) US: CAFC : Single embodiment commercial success: In re Glatt Air Techniques (Patently-O)… [read post]
2 Dec 2008, 10:07 pm
Those clients are: Novartis AG, Panasonic Corp., Qatar Investment Authority, and UBS AG. [read post]
10 Mar 2010, 5:22 am
(Patent Docs) (GenericsWeb) Protonix (Pantoprazole) - US: District Court dismisses Wyeth Lanham Act case concerning generic Protonix, but leaves the door open for further litigation (FDA Law Blog) ReFacto (Moroctocog alfa)- US: Novartis prevails over Pfizer in ReFacto suit (Patent Docs) Vytorin (Ezetimibe, Simvastatin) – US: Infringement of patent following a Paragraph IV certification: Schering Corp. et al. v. [read post]
9 Mar 2011, 3:00 am
Allergan, Inc (Chicago IP Litigation Blog) Synagis (Palivizumab) – US: PDL BioPharma settles Medimmune Synagis litigation for $93M (Patent Docs) TriCor (Fenofibrate) – US: Abbott and Elan end TriCor suit with Ranbaxy (Patent Docs) Valsartan – Norway: Oslo District Court holds Actavis’ Valsartan/HCTZ product infringes Novartis’ patent covering synthesis route for Valsartan; deals inter alia with scope of Valsartan SPC (The SPC Blog) [read post]
15 Jan 2018, 11:40 am
By age 5, they were diagnosed with autism. [read post]
2 Feb 2015, 2:20 am
Kleemans (Freshfields Bruckhaus Deringer LLP, Amsterdam) reports on the Hague Court of Appeal’s summary ruling in a case between Novartis AG and Sun Pharmaceutical Industries BV. [read post]
D.C. Circuit Review – Reviewed: It’s Not Rocket Science, But It’s Still a Matter of Agency Expertise
27 Mar 2022, 7:33 pm
Two whistleblowers argued that they were eligible for an award in connection with the SEC’s investigation of Novartis AG, a pharmaceutical company, for violations of the Foreign Corrupt Practices Act. [read post]
17 Nov 2010, 1:48 am
(Patent Baristas) A round up of international events – Access and Benefit Sharing Protocol; review of Para 6 system; concerns with ACTA’s compatibility with TRIPS(Spicy IP) Compromise UN protocol treaty against biopiracy adopted in Japan (IP Watch) (Innovation Law Blog) TRIPS Council discusses efficacy of ACTA, public health amendment (IP Watch) Altering genes in crops (IP Osgoode) Asia Pacific Pharmas moving away from generics (GenericsWeb) Belgium Commercial Court: No faultless… [read post]
27 Jul 2010, 8:20 am
” My “in group” is the group of people who are like me in salient ways such as gender, race, religion, age, educational background, profession, family status, etc. [read post]
